Morten Madsen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5284953/publications.pdf

Version: 2024-02-01

66 papers	2,561 citations	218592 26 h-index	197736 49 g-index
66 all docs	66 docs citations	66 times ranked	3017 citing authors

#	Article	IF	Citations
1	Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 577-587.	1.8	7
2	Effectiveness and Safety of Ticagrelor Implementation in Patients with Acute Coronary Syndrome undergoing Percutaneous Coronary Intervention: A Cohort Study in Western Denmark. Lancet Regional Health - Europe, The, 2022, 14, 100301.	3.0	6
3	The Socioeconomic Consequences of Cushingâ€™s Syndrome: A Nationwide Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2921-e2929.	1.8	8
4	Prediction Ability of Charlson, Elixhauser, and Rx-Risk Comorbidity Indices for Mortality in Patients with Hip Fracture. A Danish Population-Based Cohort Study from 2014 â€“ 2018. Clinical Epidemiology, 2022, Volume 14, 275-287.	1.5	7
5	Comorbidity and Quality of In-Hospital Care for Hip Fracture Patients. Journal of the American Medical Directors Association, 2022, 23, 671-677.e4.	1.2	9
6	Ten-year patterns of stent thrombosis after percutaneous coronary intervention with new- versus early-generation drug-eluting stents: insights from the DECADE cooperation. Revista Espanola De Cardiologia (English Ed), 2022, , .	0.4	5
7	Risk of Myocardial Infarction and Death After Noncardiac Surgery Performed Within the First Year After Coronary Drug-Eluting Stent Implantation for Acute Coronary Syndrome or Stable Angina Pectoris. American Journal of Cardiology, 2021, 160, 14-20.	0.7	2
8	Ten-year cardiovascular risk in diabetes patients without obstructive coronary artery disease: a retrospective Western Denmark cohort study. Cardiovascular Diabetology, 2021, 20, 23.	2.7	6
9	CHA 2 DS 2 â€VASc impact on risk following percutaneous coronary intervention in atrial fibrillation. European Journal of Clinical Investigation, 2021, , e13717.	1.7	0
10	SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. BMJ, The, 2021, 375, e068665.	3.0	179
11	Patient-related healthcare disparities in the quality of acute hip fracture care: a 10-year nationwide population-based cohort study. BMJ Open, 2021, 11, e051424.	0.8	0
12	Ten-Year Outcomes of Sirolimus-Eluting Versus Zotarolimus-Eluting Coronary Stents in Patients With Versus Without Diabetes Mellitus (SORT OUT III). American Journal of Cardiology, 2020, 125, 349-353.	0.7	5
13	A Novel Model for Prediction of Thromboembolic and Cardiovascular Events in Patients Without Atrial Fibrillation. American Journal of Cardiology, 2020, 131, 40-48.	0.7	7
14	Risk of Myocardial Infarction in Patients Without Angiographic Coronary Artery Disease Compared With the General Population. American Journal of Cardiology, 2020, 132, 8-14.	0.7	3
15	Diabetes is not a risk factor for myocardial infarction in patients without coronary artery disease: A study from the Western Denmark Heart Registry. Diabetes and Vascular Disease Research, 2020, 17, 147916412094180.	0.9	5
16	Validation of the European Society of Cardiology and European Society of Anaesthesiology non-cardiac surgery risk score in patients treated with coronary drug-eluting stent implantation. European Heart Journal Quality of Care & Clinical Outcomes, 2019, 5, 22-27.	1.8	12
17	Diabetes Mellitus Is Associated With Increased Risk of Ischemic Stroke in Patients With and Without Coronary Artery Disease. Stroke, 2019, 50, 3347-3354.	1.0	32
18	Extent of coronary artery disease is associated with myocardial infarction and mortality in patients with diabetes mellitus [Response to Letter] . Clinical Epidemiology, 2019, Volume 11, 721-722.	1.5	1

#	Article	IF	Citations
19	Impact of the Charlson Comorbidity Index score on risk prediction by single-photon emission computed tomography myocardial perfusion imaging following myocardial infarction . Clinical Epidemiology, 2019, Volume 11, 901-910.	1.5	8
20	Extent of coronary artery disease is associated with myocardial infarction and mortality in patients with diabetes mellitus . Clinical Epidemiology, 2019, Volume 11, 419-428.	1.5	13
21	Classification and characteristics of onâ€label and offâ€label apixaban use in Denmark and Sweden. Pharmacoepidemiology and Drug Safety, 2019, 28, 867-878.	0.9	5
22	Predicting stroke in patients without atrial fibrillation. European Journal of Clinical Investigation, 2019, 49, e13103.	1.7	5
23	Association between anti-diabetes treatments and cardiovascular risk in diabetes patients with and without coronary artery disease. Diabetes and Vascular Disease Research, 2019, 16, 351-359.	0.9	8
24	Comparison of Frequency of Ischemic Stroke in Patients With Versus Without Coronary Heart Disease and Without Atrial Fibrillation. American Journal of Cardiology, 2019, 123, 153-158.	0.7	10
25	Nonsteroidal Antiinflammatory Drug Use and Clinical Outcomes of Community-acquired Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 128-131.	2.5	26
26	The Western Denmark Heart Registry. Journal of the American College of Cardiology, 2018, 71, 1259-1272.	1.2	90
27	Randomized comparison of sirolimus eluting, and biolimus eluting bioresorbable polymer stents: the SORT-OUT VII optical coherence tomography study. European Heart Journal Cardiovascular Imaging, 2018, 19, 329-338.	0.5	5
28	Coronary stent implantation and adverse cardiac events after surgery. European Journal of Clinical Investigation, 2018, 48, e13030.	1.7	3
29	Neuroregeneration and Vascular Protection by Citalopram in Acute Ischemic Stroke (TALOS). Stroke, 2018, 49, 2568-2576.	1.0	50
30	Diagnostic Performance of Inâ€Procedure Angiographyâ€Derived Quantitative Flow Reserve Compared to Pressureâ€Derived Fractional Flow Reserve: The FAVOR II Europeâ€Japan Study. Journal of the American Heart Association, 2018, 7, .	1.6	240
31	Randomized clinical comparison of the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent with the sirolimus-eluting Orsiro stent in patients treated with percutaneous coronary intervention: Rationale and study design of the Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) X trial. American Heart Journal, 2018, 202, 49-53.	1.2	12
32	Rational and design of the European randomized Optical Coherence Tomography Optimized Bifurcation Event Reduction Trial (OCTOBER). American Heart Journal, 2018, 205, 97-109.	1.2	61
33	Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease. JACC: Cardiovascular Interventions, 2017, 10, 255-264.	1.1	38
34	Patients With Diabetes Without Significant Angiographic Coronary Artery Disease Have the Same Risk of Myocardial Infarction as Patients Without Diabetes in a Real-World Population Receiving Appropriate Prophylactic Treatment. Diabetes Care, 2017, 40, 1103-1110.	4.3	37
35	Coronary artery disease and risk of adverse cardiac events and stroke. European Journal of Clinical Investigation, 2017, 47, 819-828.	1.7	23
36	Dual anti-platelet therapy after coronary drug-eluting stent implantation and surgery-associated major adverse events. Thrombosis and Haemostasis, 2016, 116, 172-180.	1.8	15

#	Article	IF	Citations
37	Evaluation of algorithms for registry-based detection of acute myocardial infarction following percutaneous coronary intervention. Clinical Epidemiology, 2016, Volume 8, 415-423.	1.5	30
38	Incidence and outcomes of patients hospitalized with COPD exacerbation with and without pneumonia. International Journal of COPD, 2016, 11, 455.	0.9	53
39	Risk Associated With Surgery WithinÂ12ÂMonths After Coronary Drug-Eluting StentÂImplantation. Journal of the American College of Cardiology, 2016, 68, 2622-2632.	1.2	89
40	Gastroscopy-related adverse cardiac events and bleeding complications among patients treated with coronary stents and dual antiplatelet therapy. Endoscopy International Open, 2016, 04, E527-E533.	0.9	5
41	Invasively Measured Aortic Systolic Blood Pressure and Office Systolic Blood Pressure in Cardiovascular Risk Assessment. Hypertension, 2016, 68, 768-774.	1.3	11
42	Randomized Comparison of a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent With a Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2016, 9, .	1.4	104
43	Long-Term Outcome of Sirolimus-Eluting and Zotarolimus-Eluting Coronary Stent Implantation in Patients With and Without Diabetes Mellitus (A Danish Organization for Randomized Trials on) Tj ETQq1 1 0.784314 rgBT /Overlock	1.4	15
44	Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial. Lancet, The, 2015, 385, 1527-1535.	6.3	107
45	Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial. Lancet, The, 2014, 383, 2047-2056.	6.3	96
46	Three-Year Outcomes After Revascularization With Everolimus- andÂSirolimus-Eluting Stents From theÂSORT OUT IV Trial. JACC: Cardiovascular Interventions, 2014, 7, 840-848.	1.1	28
47	Impact of Co-morbidity on the Risk of First-Time Myocardial Infarction, Stroke, or Death After Single-Photon Emission Computed Tomography Myocardial Perfusion Imaging. American Journal of Cardiology, 2014, 114, 510-515.	0.7	6
48	Outcomes after revascularisation with everolimus- and sirolimus-eluting stents in patients with acute coronary syndromes and stable angina pectoris: a substudy of the SORT OUT IV trial. EuroIntervention, 2014, 10, 212-223.	1.4	8
49	Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. Lancet, The, 2013, 381, 661-669.	6.3	173
50	Event detection using population-based health care databases in randomized clinical trials: a novel research tool in interventional cardiology. Clinical Epidemiology, 2013, 5, 357.	1.5	21
51	Randomized Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients Treated With Percutaneous Coronary Intervention. Circulation, 2012, 125, 1246-1255.	1.6	149
52	Comparison of zotarolimus-eluting and sirolimus-eluting coronary stents: a study from the Western Denmark Heart Registry. BMC Cardiovascular Disorders, 2012, 12, 84.	0.7	2
53	2-Year Patient-Related Versus Stent-Related Outcomes. Journal of the American College of Cardiology, 2012, 60, 1140-1147.	1.2	42
54	3-Year Clinical Outcomes in the Randomized SORT OUT III Superiority Trial Comparing Zotarolimus- and Sirolimus-Eluting Coronary Stents. JACC: Cardiovascular Interventions, 2012, 5, 812-818.	1.1	43

#	Article	IF	Citations
55	Comparison of Outcomes in Patients With Versus Without Diabetes Mellitus After Revascularization With Everolimus- and Sirolimus-Eluting Stents (from the SORT OUT IV Trial). American Journal of Cardiology, 2012, 110, 1585-1591.	0.7	48
56	Influence of Diabetes Mellitus on Clinical Outcomes Following Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2012, 109, 629-635.	0.7	54
57	Zotarolimusâ€eluting vs. sirolimusâ€eluting coronary stents in patients with and without acute coronary syndromes: a SORT OUT III substudy. European Journal of Clinical Investigation, 2012, 42, 1047-1054.	1.7	10
58	Clinical outcomes after treatment of multiple lesions with zotarolimus-eluting versus sirolimus-eluting coronary stents (a SORT OUT III substudy). BMC Cardiovascular Disorders, 2012, 12, 18.	0.7	0
59	The risk and prognostic impact of definite stent thrombosis or in-stent restenosis after coronary stent implantation. EuroIntervention, 2012, 8, 591-598.	1.4	17
60	Outcome of Sirolimus-Eluting Versus Zotarolimus-Eluting Coronary Stent Implantation in Patients With and Without Diabetes Mellitus (a SORT OUT III Substudy). American Journal of Cardiology, 2011, 108, 1232-1237.	0.7	39
61	Comparison of Outcomes of Patients â‰¥80 Years of Age Having Percutaneous Coronary Intervention According to Presentation (Stable vs Unstable Angina Pectoris/Nonâ€“ST-Segment Elevation Myocardial) Tj ETQq1 1 0.784314 rgBT /Ov 1395-1400.	0.7	17
62	Outcome in high risk patients with unprotected left main coronary artery stenosis treated with percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2010, 75, 101-108.	0.7	23
63	Long-Term Outcomes After Percutaneous Coronary Intervention in Patients With and Without Diabetes Mellitus in Western Denmark. American Journal of Cardiology, 2010, 105, 1513-1519.	0.7	41
64	Existing data sources for clinical epidemiology: The Western Denmark Heart Registry. Clinical Epidemiology, 2010, 2, 137.	1.5	147
65	Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet, The, 2010, 375, 1090-1099.	6.3	198
66	Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry. EuroIntervention, 2010, 5, 898-905.	1.4	42